{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T10:19:44Z","timestamp":1765793984898,"version":"3.48.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>To compare fluctuations of central subfield retinal thickness (CSRT) in patients with neovascular age-related macular degeneration undergoing ranibizumab pro re nata versus aflibercept bimonthly treatment in a prospective 12\u2009month, phase IV, randomised, multicentre study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ranibizumab was administered according to best-corrected visual acuity (BCVA) and\/or disease activity detected on spectral domain optical coherence tomography. Aflibercept was administered at three initial monthly visits followed by bimonthly treatment. CSRT stability was evaluated between months 3 and 6. CSRT stability was compared between groups and correlated with functional outcomes at month 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fluctuations of CSRT showed a least-squares (LS) mean (95% CI) difference of \u22124.12 (\u221210.22 to 1.98) \u00b5m between ranibizumab (25.16 (20.09 to 30.24) \u00b5m) and aflibercept groups (29.28 (24.14 to 34.43) \u00b5m) (p=0.1850). A predefined analysis of retinal stability, adjusted for baseline CSRT, showed a LS mean (95%\u2009CI) difference of \u22126.53 (\u221212.47 to \u22120.58\u2009\u00b5m) in favour of ranibizumab (23.53 (18.58 to 28.49) \u00b5m) versus aflibercept (30.06 (25.04 to 35.07) \u00b5m) (p=0.0315). Pearson\u2019s correlation coefficient demonstrated no correlation between the mean amplitude of CSRT fluctuation between months 3 and 6, and BCVA at month 12 (r = \u22120.0888). Adverse event rates were low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Numerical differences in retinal thickness fluctuations between months 3 and 6 were detected between treatment regimens. While the presence of fluctuations has previously been shown to have a negative impact on functional outcomes, our data showed no correlation between the mean amplitude of fluctuations and functional outcomes at month 12.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2024-326526","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T17:20:16Z","timestamp":1753377616000},"page":"59-66","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial"],"prefix":"10.1136","volume":"110","clinical-trial-number":[{"clinical-trial-number":"nct01958918","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01958918","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hansjuergen T","family":"Agostini","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Medical Faculty, University of Freiburg, Freiburg, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-0833","authenticated-orcid":false,"given":"Rufino","family":"Silva","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hospital of the University of Coimbra, Coimbra, Portugal"}]},{"given":"Frank G","family":"Holz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Bonn, Bonn, Germany"}]},{"given":"Michael","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark"}]},{"given":"Lebriz","family":"Altay","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Cologne, Cologne, Germany"},{"name":"Department of Ophthalmology, Uniklinik Koln, Koln, Germany"}]},{"given":"Eric H","family":"Souied","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, Creteil, France"}]},{"given":"Claudia","family":"Quiering","sequence":"additional","affiliation":[{"name":"Novartis Germany, Nurnberg, Germany"}]},{"given":"Uwe","family":"Rose","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, Nurnberg, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-4372","authenticated-orcid":false,"given":"Sandra","family":"Liakopoulos","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Goethe-Universitat Frankfurt am Main, Frankfurt am Main, Germany"}]}],"member":"239","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"2025121502150598000_110.1.59.1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305702"},{"key":"2025121502150598000_110.1.59.2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"2025121502150598000_110.1.59.3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/14712598.2012.660523","article-title":"Ranibizumab for age-related macular degeneration","volume":"12","author":"Dhoot","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"2025121502150598000_110.1.59.4","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/786870","article-title":"Anti-VEGF Treatment Strategies for Wet AMD","volume":"2012","author":"Kovach","year":"2012","journal-title":"J Ophthalmol"},{"key":"2025121502150598000_110.1.59.5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/17425247.2016.1213240","article-title":"Current advances in the treatment of neovascular age-related macular degeneration","volume":"14","author":"Villegas","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"key":"2025121502150598000_110.1.59.6","first-page":"353","article-title":"Age-related macular degeneration (AMD): pathogenesis and therapy","volume":"58","author":"Nowak","year":"2006","journal-title":"Pharmacol Rep"},{"key":"2025121502150598000_110.1.59.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-012-2123-4"},{"key":"2025121502150598000_110.1.59.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"2025121502150598000_110.1.59.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"2025121502150598000_110.1.59.10","unstructured":"European Medicines Agency . Summary of product characteristics. Lucentis 10 mg\/ml solution for injection. Novartis; 2016. Available: http:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20161114136324\/anx_136324_en.pdf [Accessed 11 Jun 2018]."},{"key":"2025121502150598000_110.1.59.11","unstructured":"Department of health and human sciences. Food and Drug Administration; 2011. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2011\/125387s000ltr.pdf [Accessed 11 Jun 2018]."},{"key":"2025121502150598000_110.1.59.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"2025121502150598000_110.1.59.13","unstructured":"European Medicines Agency . Summary of product characteristics. Eylea 40 mg\/ml solution for injection in pre-filled syringe. Bayer HealthCare; 2015. Available: https:\/\/www.ema.europa.eu\/documents\/product-information\/eylea-epar-product-information_en.pdf [Accessed 9 Oct 2018]."},{"key":"2025121502150598000_110.1.59.14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5301\/EJO.2010.5766","article-title":"As-Needed Treatment with Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration","volume":"21","author":"Biarn\u00e9s","year":"2011","journal-title":"Eur J Ophthalmol"},{"key":"2025121502150598000_110.1.59.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1636-6"},{"key":"2025121502150598000_110.1.59.16","unstructured":"ClinicalTrials.gov . Available: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01958918 [Accessed 11 Jun 2018]."},{"key":"2025121502150598000_110.1.59.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.02.010"},{"key":"2025121502150598000_110.1.59.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.09.004"},{"key":"2025121502150598000_110.1.59.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.014"},{"key":"2025121502150598000_110.1.59.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.12.019"},{"key":"2025121502150598000_110.1.59.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.01.031"},{"key":"2025121502150598000_110.1.59.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.018"},{"key":"2025121502150598000_110.1.59.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.10.004"},{"key":"2025121502150598000_110.1.59.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.05.024"},{"key":"2025121502150598000_110.1.59.25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10384-009-0670-y","article-title":"One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups","volume":"53","author":"Kang","year":"2009","journal-title":"Jpn J Ophthalmol"},{"key":"2025121502150598000_110.1.59.26","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.170670"},{"key":"2025121502150598000_110.1.59.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.01.028"},{"key":"2025121502150598000_110.1.59.28","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003349"},{"key":"2025121502150598000_110.1.59.29","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"2025121502150598000_110.1.59.30","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2024-326526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T10:16:20Z","timestamp":1765793780000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2024-326526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,15]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bjo-2024-326526"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2024-326526","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"type":"print","value":"0007-1161"},{"type":"electronic","value":"1468-2079"}],"subject":[],"published":{"date-parts":[[2025,7,24]]}}}